9:54 AM
 | 
May 17, 2018
 |  BC Extra  |  Clinical News

Nektar shares dip after latest PIVOT-02 results

Nektar Therapeutics Inc. (NASDAQ:NKTR) slipped $6.57 to $79.23 on Thursday after reporting updated response rates from the Phase Ib/II PIVOT-02 study of NKTR-214 plus Opdivo nivolumab. The stock move slashed Nektar's market cap by more than $1.1 billion.

The data appeared in an abstract ahead of the American Society of Clinical Oncology meeting in...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >